Sponsored Content Originally Published by Fastco Works on Fast Company

Everyone knows radiation kills tumors. Yet traditional radiation can also cause serious side effects. But what if a treatment could minimize those side effects? TheraSphere Y-90 Glass Microspheres is doing just that. This minimally invasive form of radiation targets blood flow that normally feeds tumors. “We essentially have taken one of the cancer’s biggest strengths and used that against it,” says Peter Pattison, president of interventional oncology, peripheral interventions, at Boston Scientific, the medical device company based in Marlborough, Mass., that manufactures TheraSphere.

This remarkable innovation received FDA approval for the treatment of HCC earlier this year. Now, the Boston Scientific team is exploring how TheraSphere might be used to treat other types of tumors.

View Original Content Here

Boston Scientific

Boston Scientific

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.

More from Boston Scientific